FY2025 EPS Estimates for BeiGene Decreased by Analyst

BeiGene, Ltd. (NASDAQ:BGNE) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings estimates for shares of BeiGene in a report issued on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of $0.73 per share for the year, down from their previous forecast of $0.79. The consensus estimate for BeiGene’s current full-year earnings is ($5.00) per share. Leerink Partnrs also issued estimates for BeiGene’s FY2026 earnings at $8.11 EPS and FY2027 earnings at $13.54 EPS.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. BeiGene’s quarterly revenue was up 28.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.01 earnings per share.

BGNE has been the topic of a number of other research reports. JMP Securities started coverage on shares of BeiGene in a research note on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price target on the stock. StockNews.com upgraded shares of BeiGene from a “hold” rating to a “buy” rating in a research report on Wednesday. Citigroup increased their price target on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. TD Cowen boosted their price objective on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. raised their price objective on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $247.07.

BeiGene Stock Down 2.1 %

Shares of BGNE opened at $189.23 on Thursday. The business’s 50 day simple moving average is $212.95 and its 200-day simple moving average is $181.80. BeiGene has a 1 year low of $126.97 and a 1 year high of $248.16. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.75. The stock has a market capitalization of $18.43 billion, a price-to-earnings ratio of -22.96 and a beta of 0.63.

Institutional Trading of BeiGene

Several institutional investors and hedge funds have recently made changes to their positions in BGNE. Blue Trust Inc. increased its position in shares of BeiGene by 156.3% during the third quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after acquiring an additional 75 shares during the period. Allspring Global Investments Holdings LLC bought a new position in BeiGene in the third quarter worth approximately $36,000. Headlands Technologies LLC purchased a new position in BeiGene during the 1st quarter worth $50,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in BeiGene during the 3rd quarter valued at $67,000. Finally, SG Americas Securities LLC bought a new stake in BeiGene during the 3rd quarter valued at $105,000. 48.55% of the stock is currently owned by institutional investors.

Insider Activity at BeiGene

In other news, insider Titus B. Ball sold 137 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Xiaobin Wu sold 5,556 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total value of $1,053,695.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,070 shares of company stock worth $4,901,050. Insiders own 7.43% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.